HIGHLIGHTS
- who: Mai Zhang et al. from the Fudan University, China have published the Article: Pathological complete response in MMR-deficient/MSI-high and KRAS-mutant patient with locally advanced rectal cancer after neoadjuvant chemoradiation with immunotherapy: A case report, in the Journal: (JOURNAL)
SUMMARY
The NICHE trial showed a pathological complete response (pCR) rate of 60% in dMMR/MSIH patients after surgery, with neoadjuvant immunotherapy of ipilimumab and nivolumab. The latter phase II trial investigated the efficacy of neoadjuvant programmed cell death protein 1 (PD-1) inhibitor with celecoxib and found that the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.